Jay R. Luly Purchases 45,000 Shares of Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Stock

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) CEO Jay R. Luly acquired 45,000 shares of Enanta Pharmaceuticals stock in a transaction that occurred on Wednesday, February 12th. The shares were purchased at an average cost of $5.69 per share, with a total value of $256,050.00. Following the purchase, the chief executive officer now owns 846,638 shares of the company’s stock, valued at $4,817,370.22. This represents a 5.61 % increase in their position. The purchase was disclosed in a document filed with the SEC, which can be accessed through the SEC website.

Enanta Pharmaceuticals Trading Up 4.8 %

Shares of ENTA traded up $0.27 during mid-day trading on Wednesday, reaching $5.86. The company’s stock had a trading volume of 387,564 shares, compared to its average volume of 519,502. The stock has a market cap of $124.99 million, a PE ratio of -1.07 and a beta of 0.54. Enanta Pharmaceuticals, Inc. has a 52 week low of $4.71 and a 52 week high of $17.80. The company’s fifty day moving average price is $5.80 and its two-hundred day moving average price is $9.54.

Enanta Pharmaceuticals (NASDAQ:ENTA) last posted its quarterly earnings results on Monday, February 10th. The biotechnology company reported ($1.05) EPS for the quarter, beating analysts’ consensus estimates of ($1.16) by $0.11. Enanta Pharmaceuticals had a negative net margin of 171.57% and a negative return on equity of 73.02%. Research analysts anticipate that Enanta Pharmaceuticals, Inc. will post -5.05 EPS for the current year.

Institutional Inflows and Outflows

Institutional investors have recently added to or reduced their stakes in the stock. JPMorgan Chase & Co. raised its holdings in Enanta Pharmaceuticals by 53.7% in the 3rd quarter. JPMorgan Chase & Co. now owns 243,628 shares of the biotechnology company’s stock worth $2,524,000 after purchasing an additional 85,082 shares in the last quarter. Assenagon Asset Management S.A. boosted its holdings in shares of Enanta Pharmaceuticals by 34.1% during the 4th quarter. Assenagon Asset Management S.A. now owns 192,856 shares of the biotechnology company’s stock valued at $1,109,000 after acquiring an additional 49,050 shares during the last quarter. Barclays PLC boosted its holdings in shares of Enanta Pharmaceuticals by 294.2% during the 3rd quarter. Barclays PLC now owns 27,438 shares of the biotechnology company’s stock valued at $285,000 after acquiring an additional 20,478 shares during the last quarter. Connor Clark & Lunn Investment Management Ltd. bought a new position in shares of Enanta Pharmaceuticals in the 3rd quarter worth approximately $122,000. Finally, Geode Capital Management LLC lifted its stake in shares of Enanta Pharmaceuticals by 3.1% in the 3rd quarter. Geode Capital Management LLC now owns 477,351 shares of the biotechnology company’s stock worth $4,946,000 after purchasing an additional 14,575 shares during the period. 94.99% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

ENTA has been the subject of several recent analyst reports. JMP Securities reaffirmed a “market outperform” rating and set a $21.00 price objective on shares of Enanta Pharmaceuticals in a research note on Tuesday. HC Wainwright reaffirmed a “buy” rating and set a $18.00 price objective on shares of Enanta Pharmaceuticals in a research note on Tuesday. StockNews.com cut shares of Enanta Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Tuesday. Finally, Robert W. Baird reduced their price objective on shares of Enanta Pharmaceuticals from $26.00 to $20.00 and set an “outperform” rating for the company in a research note on Tuesday, November 26th. Two analysts have rated the stock with a sell rating, three have given a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $17.25.

About Enanta Pharmaceuticals

Enanta Pharmaceuticals, Inc, a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; EDP-938 and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses; and Glecaprevir, which is in the market for the treatment of chronic infection with hepatitis C virus or HCV.